Haematological toxicity associated with antineoplastic drugs: a pharmacovigilance analysis based on the FDA adverse event reporting system database
A retrospective pharmacovigilance study using FAERS data covering the period from 2004 Q1 to 2025 Q4 reveals a strong signal of haematological toxicity associated with antitumour agents, supporting enhanced routine monitoring to mitigate clinical risks.